Otezla is the first and only oral therapy approved across all severities of adult plaque psoriasis SEE NEW DATA
Study Design 2,3

In ESTEEM 1, patients were switched to Otezla if they lost their PASI-75, but no later than at week 52.2 In ESTEEM 2, patients were switched to Otezla if they lost 50% of the PASI improvement obtained at week 32 compared to baseline, but no later than at week 52.
*Doses of Otezla were titrated during the first week of administration. †A responder was defined as a patient achieving ≥PASI-75; a partial responder was defined as a patient achieving PASI-50 to PASI-74; a nonresponder was defined as a patient achieving <PASI-50 in both ESTEEM 1 and ESTEEM 2 at week 32. ‡At week 32, nonresponders and partial responders (ESTEEM 1) or nonresponders only (ESTEEM 2) had the option of adding topical and/or UVB therapy. The decision could be made at week 32 and was based on the discretion of the investigator.
- Evaluated in 2 multicenter, double-blind, placebo-controlled trials of similar design. Patients with moderate to severe plaque psoriasis (N=1257) were randomized 2:1 to Otezla 30 mg BID or placebo for 16 weeks after a 5-day titration 1
- At week 16, all patients originally assigned to placebo transitioned to Otezla 30 mg BID. At week 32, some patients originally randomized to Otezla were, based on clinical response, re-randomized to Otezla or placebo. Those re-randomized to placebo restarted Otezla 30 mg BID at loss of response, but no later than at week 52 2,3
- Patients entering a long-term extension phase could be treated through 5 years 2,3